Amryt Pharma (NASDAQ:AMYT) and IMARA (NASDAQ:IMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Profitability
This table compares Amryt Pharma and IMARA's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Amryt Pharma | N/A | N/A | N/A |
IMARA | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of recent recommendations for Amryt Pharma and IMARA, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Amryt Pharma | 0 | 1 | 3 | 0 | 2.75 |
IMARA | 0 | 0 | 3 | 0 | 3.00 |
Amryt Pharma currently has a consensus price target of $38.00, indicating a potential upside of 174.37%. IMARA has a consensus price target of $35.3333, indicating a potential upside of 384.68%. Given IMARA's stronger consensus rating and higher possible upside, analysts plainly believe IMARA is more favorable than Amryt Pharma.
Valuation and Earnings
This table compares Amryt Pharma and IMARA's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Amryt Pharma | $58.12 million | 8.55 | $-30,854,220.00 | ($0.86) | -16.11 |
IMARA | N/A | N/A | N/A | N/A | N/A |
IMARA has lower revenue, but higher earnings than Amryt Pharma.
Institutional and Insider Ownership
15.4% of Amryt Pharma shares are owned by institutional investors. Comparatively, 64.5% of IMARA shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
IMARA beats Amryt Pharma on 3 of the 4 factors compared between the two stocks.